Advanced Filters
noise

t-cell-lymphoma Clinical Trials

A listing of t-cell-lymphoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 148 clinical trials
G Guillaume Cartron, Prof.

A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype

The study will evaluate the progression-free survival benefit of duvelisib monotherapy as compared to investigator's choice of gemcitabine or bendamustine in participants with relapsed/refractory nodal T cell lymphoma with TFH phenotype.

18 years of age All Phase 3
L Lucie-Anne Casper

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, and preliminary clinical activity of Tulmimetostat as a monotherapy in patients with advanced solid tumors and lymphomas.

18 years of age All Phase 1/2
E Eric Jacobsen, MD

Tazemetostat Plus CHOP in 1L T-cell Lymphoma

This research is being done to evaluate tazemetostat in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy as a possible treatment for peripheral T-Cell Lymphoma (PTCL). The name of the study drugs involved in this study are: Tazemetostat (a type of inhibitor for Enhancer of Zeste Homolog 2 (EZH2)) Standard …

18 years of age All Phase 2
J JingZe Zuo

A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma

Primary Objective To evaluate the preliminary efficacy of Purinostat Mesylate for Injection in patients with relapsed or refractory Peripheral T-Cell Lymphoma (PTCL) and Cutaneous T-Cell Lymphoma (CTCL). Secondary Objectives To evaluate the safety and tolerability of Purinostat Mesylate for Injection in patients with relapsed or refractory PTCL and CTCL. To …

18 years of age All Phase 2

Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma

Background Lymphoma is a type of blood cancer. Blood cell transplant can cure some people with lymphoma. Researchers want to see if they can limit the complications transplant can cause. Objective To test if a stem cell transplant can cure or control lymphoma. Also to test if new ways of …

12 - 120 years of age All Phase 2
J Jana Hall Project Manager

CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma

This is a research study to determine the safety and tolerability of ATLCAR.CD30 for treating relapsed/refractory Peripheral T Cell Lymphoma. Blood samples will be collected from study participants and the immune T cells will be separated. T cells will be genetically modified in a laboratory at UNC-Chapel Hill to enable …

18 - 99 years of age All Phase 2
L Li Yu

CD7 CAR-T Cells in T-cell Lymphoma/Leukemia

T-cell lymphoma/leukemia is a group of highly lethal diseases with a high relapse rate and poor prognosis. CD7 was proved to be widely expressed in T-cell malignant, which makes it a promising therapeutic target. In this study we aim to test the safety and efficacy of CD7 CAR-T cells in …

18 - 75 years of age All Phase N/A

Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL)

This is a single-center, phase I/IB study to identify the recommended phase II dose of Ropeginterferon-alfa 2b (P1101) in patients with CTCL who have failed at least two prior lines of skin-directed therapy (Stage IA-IB) or have less than a complete response to phototherapy or extracorporeal photopheresis (ECP) or total …

18 years of age All Phase 1
D Dongmei Ji, M.D

Sintilimab Combined With Chidamide in Treating Peripheral T Cell Lymphoma

This is a single-center, single-arm, phase 2 study to evaluate the efficacy and safety of Anti-PD-1 antibody(Sintilimab) plus HDAC inhibitor(Chidamide) in patients with relapsed/refractory peripheral T-cell lymphoma (r/r PTCL).

18 - 75 years of age All Phase 2
E Emmanuel Bachy, Dr.

Transplantation After Complete Response In Patients With T-cell Lymphoma

Peripheral T-cell lymphoma (PTCL) encompasses a broad range of post-thymic (i.e., mature) sub-entities as defined by the 2017 WHO classification. The most common entities are angioimmunoblastic T-cell lymphoma (AITL) and other Tfh-phenotype PTCL or PTCL not otherwise specified (NOS), each representing approximately 20 to 25% of mature T- and NK/T-cell …

18 - 70 years of age All Phase N/A

Simplify language using AI